| GTO ID | GTC3798 |
| Trial ID | NCT06305767 |
| Disease | Bladder Cancer |
| Therapy | mRNA vaccine |
| Treatment | V940|mRNA-4157 |
| Co-treatment | Pembrolizumab |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase 2, Randomized, Double-blind, Placebo- and Active-comparator Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-risk Muscle-invasive Urothelial Carcinoma Post-radical Resection |
| Year | 2024 |
| Country | United States |
| Company sponsor | Merck Sharp & Dohme LLC |
| Other ID(s) | V940-005|V940-005|U1111-1292-1952|2023-505658-17 |
| Vector information | |||
|
|||
| Cohort1: V940 | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||